Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Two-cohort, Double-blind, Randomized, Placebo-controlled, Multicenter Phase 1/2 Study to Evaluate the Safety, Tolerability and Efficacy of REJUVEINIX (RJX) in Patients With COVID-19

NCT04708340 is registered in ClinicalTrials.gov with Reven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04708340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04708340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Two-cohort, Double-blind, Randomized, Placebo-controlled, Multicenter Phase 1/2 Study to Evaluate the Safety, Tolerability and Efficacy of REJUVEINIX (RJX) in Patients With COVID-19
Lead sponsor
Reven Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 25, 2021
Completion date
February 28, 2023
Enrollment
237 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, covid-19, hypoxemia, sars-cov-2